Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease

Journal of Chemical Information and Computer Sciences

Volumn 43, Issue 4, 2003, Pages 1297-1307

  Senese, Craig L ^a   Hopfinger, A J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES;

AMINO ACIDS; DRUG PRODUCTS; HYDROPHOBICITY; MORPHOLOGY; PROTEINS; VIRUSES;

ENZYME INHIBITION;

3 AMINO 2 HYDROXY 5 METHYLHEXANOIC ACID; 3-AMINO-2-HYDROXY-5-METHYLHEXANOIC ACID; AMINOCAPROIC ACID DERIVATIVE; ARYLBUTYRIC ACID DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY;

AMINOCAPROIC ACIDS; BINDING SITES; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENYLBUTYRATES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SENSITIVITY AND SPECIFICITY;

EID: 0041698437     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci0340456     Document Type: Article

References (25)

1. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schenider, J.; Kent, S. B. H. Structure of complex of synthetic HIV-1 Protease with a substrate-based inhibitor at 2.3 Å resolution. Science 1989, 246, 1149-1152.
2. Navia, M. A.; Fitzgerald, P. M. D.; McKeever, B. M.; Leu, C.-T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989, 337, 615-620.
3. Roberts, N. A.; Craig, J. C.; Duncan, I. B. HIV proteinase inhibitors. Bio. Soc. Trans. 1992, 20, 513-516.
4. Sakurai, M.; Sugano, M.; Handa, H.; Komai, T.; Yagi, R.; Nishigaki, T.; Yabe, Y. Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple amino alcohol, and statine analogue at the scissile site of substrate sequences. Chem. Pharm. Bull 1993, 41, 1369-1377.
5. Kaldor, S. W.; Kalish, V. J.; Davies, J. F.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Pressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patrick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
6. De Lucca, G. V.; Liang, J.; Aldrich, P. E.; Calabrese, J.; Cordova, B.; Klabe, R. M.; Rayner, M. M.; Chang, C.-H. Design, synthesis, and evaluation of tetrahydropyrimidines as an example of a general approach to nonpeptide HIV protease inhibitors. J. Med. Chem. 1997, 40, 1707-1719.
7. Gupta, S. P.; Babu, M. S. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors. Bioorg. Med. Chem. 1999, 7, 2549-2553.
8. Hagen, S. E.; Domagala, J.; Gajda, C.; Lovdahl, M.; Tait, B. D.; Wise, E.; Holler, T.; Hupe, D.; Nouhan, C.; Urumov, A.; Zeikus, G.; Zeikus, E.; Lunney, E. A.; Pavlovsky, A.; Gracheck, S. J.; Saunders: J.; VanderRoest, S.; Brodfuehrer, J. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J. Med. Chem. 2001, 44, 2319-2332.
9. Ratner, L.; Haseltine, W.; Patarca, R.; Llvak, K. J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Ratalski, J. A.; Whitehorn, E. A.; Baumeister, K.; Ivanoff, L.; Petteway, S. R.; Pearson, M. L.; Lautenberger, J. A.; Papas, T. S.; Ghrayeb, J.; Chang, N. T.; Gallo, R. C.; Wong-Staal, F. Complete nucleotide sequence of the AIDS virus, HLTV-III. Nature (London) 1985, 313, 277-284.
10. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Meimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 55, 4686-4690.
11. Ashorn, P.; McQuade, T. J.; Thaisrivongs, S.; Tomasselli, A. G.; Tarpley, W. G.; Moss, B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7472-7476.
12. McQuade, T. J.; Tomasselli, A. G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T. K.; Heinrikson, R. L.; Ratpley, W. G. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 1990, 247, 454-456.
13. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248, 358-361.
14. Sakurai, M.; Higashida, S.; Sugano, M.; Komai, T.; Yagi, R.; Ozawa, Y.; Handa, H.; Nishigaki, T.; Yabe, Y. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA. Bioorg. Med. Chem. 1994, 2, 807-825.
15. Komai, T.; Higashida, S.; Sakurai, M.; Nitta, T.; Kasuya, A.; Miyamaoto, S.; Yagi, R.; Ozawa, Y.; Handa, H.; Mohri, H.; Yasuoka, A.; Oka, S.; Nishigaki, T.; Kimura, S.; Shimada, K.; Yabe, Y. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA II. Modification of pyrrolidine ring at P1′ proline. Bioorg. Med. Chem. 1996, 4, 1365-1377.
16. Takashiro, E.; Wantanabe, T.; Nitta, T.; Kasuya, A.; Miyamoto, S.; Ozawa, Y.; Yagi, R.; Nishigaki, T.; Shibayama, T.; Nakagawa, A.; Iwamoto, A.; Yabe, Y. Structure-activity relationships of HIV-1 protease inhibitors containing AHPBA III. Modification of P2 site. Bioorg. Med. Chem. 1998, 6, 595-604.
17. Huang, X.; Xu, L.; Luo, X.; Fan, K.; Ji, R.; Pei, G.; Chen, K.; Jiang, H. Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. J. Med. Chem. 2002, 45, 333-343.
18. Hopfinger, A. J.; Wang, S.; Tokarski, J. S.; Jin, B.; Albuquerque, M.; Madhav, P. J.; Duraiswami, G. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc. 1997, 119, 10509-10524.
19. 4D-QSAR, Version 3.0; The Chem21 Group, Inc., 1780 Wilson Drive, Lake Forest, IL 60045, 2002.
20. HyperChem Program Release 6.01 for Windows; Hypercube, Inc., 2000.
21. MOLSIM V3.0; D. C. Doherty and The Chem21 Group, Inc., 1780 Wilson Drive, Lake Forest IL 60045, 1998.
22. Rogers, D.; Hopfinger, A. J. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866.
23. Terfloth, L.; Gasteiger, S. Neural networks and genetic algorithms in drug design. Drug Discovery Today 6 (15 suppl) 2001, s102-s108.
24. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
25. Kleinbaum, D. G.; Lawrence, L. K.; Muller, K. E.; Nizam, A. Applied regression analysis and other multivariate methods, 3rd ed.; Brooks/Cole Publishing Co.: CA, 1998.